Healthy WomenNCT07793123
Effect of an Antioxidant Dietary Supplement on Skin Radiance
A study testing Antioxidant Supplement in people with Healthy Women, run by Robertet SA at 1 site in France.
Trial summary
A randomized, double-blind, placebo-controlled study evaluating the effects of an oral antioxidant dietary supplement on skin radiance in women exposed to urban air pollution. Secondary assessments include skin tone homogeneity, pigmentation, inflammation, skin barrier function, glycation markers. Read more about this study
- Who is it for?
- Ages 35 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Women
- What is being tested?
- Antioxidant Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 31 Aug 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy female subjects aged 35 to 65 years.
- Fitzpatrick skin phototype II to IV.
- Any skin type.
- Dull and uneven skin complexion.
- Living in an urban environment and exposed to pollution.
- No change in hormonal treatment within the past 3 months.
Show all 11Show fewer
- Able to understand the study procedures and provide informed consent.
- Willing and able to comply with study requirements.
- Written informed consent obtained.
- Covered by health insurance.
- Willing to avoid unprotected sun exposure and use SPF 50 sunscreen throughout the study.
Who cannot join
- Pregnant or breastfeeding women, or women planning to become pregnant during the study.
- Current use of dietary supplements or vitamin supplements.
- Participation in another clinical trial involving a cosmetic product, drug, or medical device.
- Use of oral or injectable corticosteroids within the past 3 months.
- Current treatment with immunosuppressive agents, chemotherapy, or radiotherapy.
- History of autoimmune disease or connective tissue disorder.
Show all 11Show fewer
- Presence of an active dermatological condition that could affect study assessments.
- Following a vegetarian, vegan, or weight-loss diet.
- Not covered by health insurance.
- Participation in another clinical study during the exclusion period.
- Individuals considered vulnerable according to applicable regulations.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomized Double-Blind Placebo-Controlled Trial Evaluating the Effect of an Oral Antioxidant Dietary Supplement on Skin Radiance in Women Exposed to Urban Air Pollution
A randomized, double-blind, placebo-controlled study evaluating the effects of an oral antioxidant dietary supplement on skin radiance in women exposed to urban air pollution. Secondary assessments include skin tone homogeneity, pigmentation, inflammation, skin barrier function, glycation markers.
- Conditions
- Healthy Women
- Being tested
- Antioxidant Supplement, Placebo
- Keywords
- Skin, pollution, Radiance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antioxidant SupplementDietary supplement
Oral antioxidant dietary supplement administered as one capsule once daily for 90 days.
PlaceboDietary supplement
Placebo dietary supplement administered as one capsule once daily for 90 days.
| Study group | Role | What they receive |
|---|---|---|
| Dietary supplement : Placebo | Placebo comparator | Maltodextrin = 400 mg/capsule, 1 capsule per day. Receives: Dietary Supplement: Placebo |
| Dietary supplement : Investigational product | Active comparator | 1 capsule contains :140 mg Rosa damascena extract, 20 mg melon concentrate and 140 mg acerola extract; 57mg maltodextrin; 1 capsule per day. Receives: Dietary Supplement: Antioxidant Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Radiance
Glossymeter
Measured: Day 0 and Day 90
Secondary outcomes (7)
Skin Radiance
Glossymeter
Measured: Day 0 and Day 30
Skin Radiance
Clinical scoring
Measured: Day 0, Day 30, Day 90
Skin homogeneity
VISIA CR5
Measured: Day 0, Day 30, Day 90
Skin homogeneity
Chromameter
Measured: Day 0, Day 30, Day 90
TransEpidermal Water Loss
Tewameter
Measured: Day 0, Day 30, Day 90
Skin glycation
AGEscanner
Measured: Day 0, Day 30, Day 90
skin IL8
IL8 assay
Measured: Day 0, Day 30, Day 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2026
- Study start31 Aug 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy WomenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Robertet SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07793123
- Sponsor's protocol ID
- ID-RCB: 2026-A00933-48
- Status last verified
- Jul 2026
- First submitted
- 31 Jul 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Double-Blind Placebo-Controlled Trial Evaluating the Effect of an Oral Antioxidant Dietary Supplement on Skin Radiance in Women Exposed to Urban Air Pollution
- ClinicalTrials.gov ID
- NCT07793123
- Acronym / sponsor ID
- ID-RCB: 2026-A00933-48
- Conditions
- Healthy Women
- Keywords
- Skin, pollution, Radiance
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Robertet SAIndustry (pharma, biotech, devices)
- Study start
- 31 Aug 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 28 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, double-blind, placebo-controlled study evaluating the effects of an oral antioxidant dietary supplement on skin radiance in women exposed to urban air pollution. Secondary assessments include skin tone homogeneity, pigmentation, inflammation, skin barrier function, glycation markers.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dietary supplement : Placebo | Placebo comparator | Dietary Supplement: PlaceboMaltodextrin = 400 mg/capsule, 1 capsule per day. |
| Dietary supplement : Investigational product | Active comparator | Dietary Supplement: Antioxidant Supplement1 capsule contains :140 mg Rosa damascena extract, 20 mg melon concentrate and 140 mg acerola extract; 57mg maltodextrin; 1 capsule per day. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Healthy female subjects aged 35 to 65 years.
- Fitzpatrick skin phototype II to IV.
- Any skin type.
- Dull and uneven skin complexion.
- Living in an urban environment and exposed to pollution.
Key exclusion criteria (11 listed)
- Pregnant or breastfeeding women, or women planning to become pregnant during the study.
- Current use of dietary supplements or vitamin supplements.
- Participation in another clinical trial involving a cosmetic product, drug, or medical device.
- Use of oral or injectable corticosteroids within the past 3 months.
- Current treatment with immunosuppressive agents, chemotherapy, or radiotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antioxidant SupplementOral antioxidant dietary supplement administered as one capsule once daily for 90 days. | Dietary supplement | Dietary supplement : Investigational product |
| PlaceboPlacebo dietary supplement administered as one capsule once daily for 90 days. | Dietary supplement | Dietary supplement : Placebo |
Primary outcome
Skin Radiance
Time frame: Day 0 and Day 90
Glossymeter
7 secondary outcomes
Skin Radiance
Time frame: Day 0 and Day 30
Skin Radiance
Time frame: Day 0, Day 30, Day 90
Skin homogeneity
Time frame: Day 0, Day 30, Day 90
Skin homogeneity
Time frame: Day 0, Day 30, Day 90
TransEpidermal Water Loss
Time frame: Day 0, Day 30, Day 90
Skin glycation
Time frame: Day 0, Day 30, Day 90
skin IL8
Time frame: Day 0, Day 30, Day 90
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy Women
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Healthy Female Participants
Not yet recruitingPhase 1
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)
Healthy, Renal Impairment
RecruitingPhase 1
A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
Participants With Moderate and Severe Renal Impairment and Healthy Participants
Recruiting
The Effect of Water Temperature on Heart Rate Variability and Cognition
Mental Acuity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Antioxidant Supplement in people with Healthy Women, run by Robertet SA at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Radiance (time frame: Day 0 and Day 90). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.